BridgeBio Comes Back With Positive Phase III Results For Acoramidis In ATTR-CM
The ATTRibute-CM study met its primary endpoint as well as key secondary endpoints, and the company plans to file for US FDA approval before the end of 2023.
The ATTRibute-CM study met its primary endpoint as well as key secondary endpoints, and the company plans to file for US FDA approval before the end of 2023.